Biotech VC Funds

OpenView Venture Partners, based in Boston, is a leading venture capital firm focused on expansion-stage B2B software companies. Founded in 2006 by Scott Maxwell, OpenView specializes in product-led growth (PLG), backing high-potential startups in sectors like SaaS, cloud computing, and productivity software. Notable investments include companies like Calendly, Expensify, and UserTesting, which have scaled into industry leaders with the firm’s support. OpenView typically invests between $5 million and $15 million, focusing on companies with $2 million to $20 million in revenue. Their strategy revolves around more than just capital; they provide operational expertise, assisting with areas like pricing, go-to-market strategy, and talent acquisition. Their value-add model means they work closely with portfolio companies to optimize growth and operational efficiency, helping founders build sustainable and scalable businesses. Geographically, OpenView invests primarily in North America, with a keen eye for businesses that are ready to transition from early traction to full-scale market dominance. The firm is known for its deep expertise in the enterprise software space and is selective about partnering with companies that align with its product-led growth thesis. The leadership team, including key partners like Blake Bartlett and John McCullough, are hands-on with portfolio companies, often playing a pivotal role in key hires and strategic decisions. OpenView is particularly known for its content and community efforts, offering valuable industry insights and resources to help software leaders grow faster.

Operator Partners is a venture capital firm that uniquely operates with its own capital, investing in technology companies from the pre-seed to Series B stages. Founded and led by experienced entrepreneurs, the firm provides support beyond financial investment, focusing on helping companies with business building and scaling challenges that arise between board meetings. Operator Partners has a hands-on approach, offering guidance based on their own entrepreneurial experiences. They engage with founders on various aspects such as product development, customer acquisition, fundraising, recruiting, and establishing organizational culture. The firm does not lead funding rounds or take board seats but assists in finding lead investors if needed. The team includes General Partners Amit Avner, Gil Shklarski, Nat Turner, and Zach Weinberg, along with Partner Olivia Benjamin. This team brings extensive expertise from founding and scaling successful companies themselves, making them well-equipped to support their portfolio companies effectively.

Optum Ventures is an independent venture capital firm founded in November 2017 as a strategic partnership between UnitedHealth Group and its Optum subsidiary. Headquartered in Boston, Massachusetts with a second office in Menlo Park and London presence, the firm launched with an initial $250 million commitment and has since scaled to over $2 billion in assets under management across six successive funds. Its mission is to back the next generation of healthcare innovation, investing stage-agnostically from seed through growth equity in companies at the intersection of technology and healthcare. Partners include A.G. Breitenstein, Virginia McFerran, and Heather Roxborough. Optum Ventures leads rounds and its thematic priorities include digital health, data analytics, value-based care delivery, healthcare enterprise software, clinical AI, fintech and insurtech applied to healthcare, and enabling health-system infrastructure. The firm has deployed capital into more than 120 companies and holds five unicorns: Ambience, an AI ambient scribe company; DispatchHealth; and LetsGetChecked, among others. Recent activity includes Risa Labs in January 2026 as the most recent disclosed investment; Reema Health at Series B in December 2025; Headstart, an ABA autism-care platform backed in 2025; and CoPlane, which raised a $14 million seed round in 2025 for AI-native ERP workflow automation. Optum Ventures' differentiation lies in its deep commercial connectivity to UnitedHealth Group — the largest US health insurer and services company. Portfolio companies gain access to health plans, providers, employers, and patients through the UHG network, as well as Optum's health-services commercialization expertise. This combination of financial capital and strategic distribution makes Optum Ventures one of the most consequential healthcare-focused CVCs in the market.

OrbiMed is a leading healthcare-focused investment firm based in New York City, established in 1989. It manages over $18 billion in assets across various investment strategies, including public equity, private equity, and private credit/royalty investments. OrbiMed invests globally in companies spanning the healthcare sector, from biopharmaceuticals to medical devices and healthcare services. OrbiMed’s portfolio includes notable companies like Guardant Health, Adaptive Biotechnologies, and Apollomics, showcasing its strong presence in the biotech and medical device sectors. The firm is known for its ability to back innovative startups and has been instrumental in bringing over 60 new healthcare therapies to market​ ​. For startups and established companies looking to connect with OrbiMed, it is beneficial to demonstrate innovative healthcare solutions with strong potential for market impact. The firm typically leads investment rounds and provides significant strategic support to help companies grow into market leaders.

Oregon Venture Fund (OVF) is Portland's largest and most active early-stage technology investor, founded in 2007 as the Oregon Angel Fund and rebranded in 2018 to reflect its evolution into a fully institutional venture vehicle. Managing Partner Eric Rosenfeld co-founded the firm and leads a platform that has grown to approximately $250 million in cumulative AUM, deploying $15 to $20 million annually through an annual-vintage model. Each year OVF forms a new limited partnership drawing from a community of 180-plus accredited venture partners who serve as both LPs and as active advisors, operators, and deal introducers for portfolio companies. The fund focuses exclusively on Oregon and Southwest Washington companies across stages from seed through Series B, with initial checks of $500,000 to $4 million and total reserves of up to $10 million per company. OVF leads rounds and has backed over 70 portfolio companies, including Absci (NASDAQ: ABSI, the largest biotech IPO in Greater Oregon history at $230 million), Jama Software, Elemental Technologies, Brandlive, Salt and Straw, Wildfang, Conveyor, Hydrolix, and Lumen Learning. Through 2021 the firm reported a 34 percent average annual rate of return and a 3.5x gross multiple. OVF invests across software, biotech, health technology, food and beverage, and AI, reflecting the diverse character of the Pacific Northwest technology ecosystem it helped build. The firm's community-LP model means that portfolio founders gain not just capital but introductions to operators and executives with deep Pacific Northwest networks, giving OVF a differentiated value proposition relative to coastal generalist funds.

ORIX Growth Capital (formerly ORIX Venture Finance and ORIX Ventures) is the growth-finance and venture-debt business of ORIX Corporation USA, the US hub of Tokyo-listed international financial services group ORIX Corporation, which operates across 30 countries. Founded in 2001 and headquartered in New York with additional presence in Dallas, the group rebranded to ORIX Growth Capital to better reflect its positioning as a specialist provider of debt and equity capital to venture-backed, high-growth companies rather than a traditional equity VC. The platform is led by Jeff Bede as Head of Growth Capital, alongside Managing Directors David Orlandella and Benjamin Wu, who heads the East Coast practice. Orix Growth Capital is an enterprise-value lender that scales individual facilities from $5 million to $100 million and deploys across the full capital stack, including senior secured unitranche, second-lien facilities, subordinated venture debt, and equity co-investments. Typical terms include five-year maturities, extended interest-only periods, and delayed-draw capability. Sector focus centers on technology and healthcare, spanning SaaS, software, biotech, fintech, and data analytics. Since 2001 the group has provided approximately $2.5 billion in financing to more than 200 companies and has recorded 45 portfolio exits. Recent activity includes a debt facility for Piano Software alongside Updata Partners' Series D equity round in February 2025. The firm leads transactions and provides capital-structure solutions that complement rather than compete with equity investors, giving founders growth runway with flexible repayment structures designed for SaaS and healthcare business models.

Oriza Ventures is a venture capital fund that focuses on early-stage technology investments, primarily in North America. Founded by seasoned entrepreneurs and investors, Oriza Ventures supports startups with disruptive technological pursuits and innovative business ideas. The firm's portfolio spans various industries, including artificial intelligence, big data, Internet of Things, consumer internet, and medical and health products. The team at Oriza Ventures includes founding partners John Yu, Alex Liang, and Yao Xiao, who bring extensive experience in venture capital and entrepreneurship. They leverage their backgrounds to provide strategic guidance and resources to their portfolio companies. Oriza Ventures' portfolio features a diverse range of companies such as Ayla Networks, an IoT platform for smart home appliances; Bolt, an online checkout platform; and InterVenn Biosciences, which uses AI-driven mass spectrometry for medical applications.

Orlando Health Ventures is the corporate venture capital arm of Orlando Health, one of Central Florida's largest nonprofit integrated healthcare systems, established in 2018 and based in Orlando, Florida. The unit sits inside the Orlando Health Strategic Innovations group alongside The Foundry, Orlando Health's internal innovation and rapid-prototyping engine, giving portfolio companies direct access to clinicians, operating executives, and service-line leaders for evaluation, piloting, and commercial validation. The fund targets early-stage companies whose technologies have the potential to transform care delivery, clinical workflows, and patient outcomes. Orlando Health Ventures has made approximately nine disclosed investments concentrated in medical devices and digital health. Portfolio companies include 410 Medical (rapid IV medication delivery, with a Series B-II round in March 2025 as the firm's most recent disclosed investment), Biostable Science and Engineering (Austin-based heart-valve repair device as an alternative to replacement, with roughly $1.25 million deployed), and Vesalio (neurovascular thrombectomy devices whose NeVa VS system launched at Wellstar Health System in Atlanta). The fund participates in seed through Series B rounds alongside peer health-system corporate venture arms such as UPMC Enterprises. What distinguishes Orlando Health Ventures is its combination of clinician-led diligence and operational pilot capability. Portfolio companies can run structured pilots within the Orlando Health system, gaining real-world evidence and commercial traction while the fund's investment committee evaluates growth trajectory and return potential. The result is a capital partner that brings both funding and a credible path to enterprise healthcare customers.

OS Fund, established in 2014 by Bryan Johnson, is a venture capital firm that invests in early-stage science and technology companies. The firm focuses on sectors such as genomics, synthetic biology, computationally derived therapeutics, advanced materials, and diagnostics. The goal is to support companies that are developing groundbreaking technologies and solutions to solve significant real-world challenges​. Bryan Johnson, who co-founded the fund, initially invested $100 million of his own money after selling his previous company, Braintree, to PayPal for $800 million. The fund seeks out entrepreneurs who are future-oriented and possess the ambition to create a better future for humanity​. OS Fund has a strong portfolio, including companies like Ginkgo Bioworks, Atomwise, and Verge Genomics. These companies are at the forefront of innovation, working on projects such as self-fertilizing crops, storing data in DNA, and designing new proteins.

Osage Venture Partners (OVP) is a Philadelphia-based venture capital firm that specializes in early-stage investments in B2B software companies. The firm primarily focuses on companies driving innovation in the future of work and education sectors. Since its inception, OVP has invested in over 30 companies, with a strong preference for those with recurring revenue models and deep domain expertise. Notable investments in their portfolio include companies like Sidecar, RiskLens, and ExecOnline. OVP typically invests in post-revenue companies with a revenue run rate between $500,000 and $3 million, focusing mainly on Seed and Series A rounds. They have a hands-on approach, often leading or co-leading investments and joining the boards of their portfolio companies. OVP emphasizes the importance of partnerships, leveraging their extensive network of technology executives and industry experts to support the growth and success of the companies they invest in. Their team is comprised of seasoned investors and former operators who provide strategic guidance and operational support to entrepreneurs.

OSF Ventures is the corporate venture capital arm of OSF HealthCare, a 15-hospital nonprofit integrated health system operating across Illinois and Michigan. Founded in 2015 and headquartered in Peoria, Illinois, OSF Ventures sits within OSF Innovation and invests financially, operationally, and strategically in healthcare companies whose technologies can improve patient outcomes, enhance patient experience, and reduce the cost of care. Mayank Taneja, Vice President of Venture Investments, leads a seven-person team across three successive fund vintages that have grown cumulative AUM to $250 million, anchored by Fund III, a $100 million vehicle launched in January 2022 with a thesis tilt toward alternative care modalities and healthcare workforce retention. The firm participates as a syndicate member at Series A through growth stages and has made approximately 37 investments spanning health information technology, medical devices, therapeutics, diagnostics, and technology-enabled care delivery. The portfolio has produced notable exits including Current Health (acquired by Best Buy in 2021), Health Catalyst (NASDAQ IPO in 2019), and SilverCloud Health (acquired by Amwell in 2021). Recent deployments include Hellocare.ai, Cala, ShiraTronics, Cardiosense ($15.1 million Series A for an AI heart disease biomarker platform), 410 Medical ($6.3 million Series B for pediatric sepsis), and Digital Diagnostics ($75 million Series B, autonomous AI diagnostics). OSF Ventures brings more than just capital to portfolio companies. Its status as an active operating health system means founders gain access to clinical validation environments, practitioner networks, and patient populations that can meaningfully accelerate regulatory and commercial timelines, making the fund a strategic partner in addition to a financial backer.

OTV (formerly Olive Tree Ventures) is a global specialist venture capital firm exclusively dedicated to digital health, founded in 2015 and headquartered in Tel Aviv, Israel with additional offices in New York, Montreal, and Shanghai. Co-founded by General Partners Mayer Gniwisch, Amir Lahat, and Alejandro Weinstein, who together bring backgrounds spanning healthcare, technology, private equity, and financial services, the firm is widely recognized as Israel's only major VC whose primary investment focus is digital health. Partner Manor Zemer complements the founding team. OTV closed a dedicated $170 million digital-health growth fund in December 2020, anchoring its international expansion including the opening of its Asia office in Shanghai. The firm leads rounds across 45 investments and covers the full arc of digital health: telemedicine and virtual care, genomics, AI-powered clinical decision and diagnostics platforms, digital biomarkers, precision medicine, and next-generation medical-device software. Notable portfolio companies include TytoCare (remote examination kit, whose $50 million round OTV led alongside Insight Partners and Qualcomm Ventures) and Scopio Labs ($16 million Series B that OTV led in December 2023, advancing digital microscopy and AI pathology). Realized exits include Lemonaid Health (acquired by 23andMe) and Emedgene (acquired by Illumina). OTV focuses particularly on companies reaching commercial maturity, partnering with founders to navigate regulatory, reimbursement, and enterprise sales challenges across five continents. Its combination of Israeli innovation sourcing, US capital-market relationships, and Asian commercial networks makes it a genuinely global platform for digital health at growth stage.

OurCrowd, founded in 2013 and headquartered in Jerusalem, is a leading global venture capital platform. It offers accredited investors access to pre-vetted startups, exclusive venture funds, and alternative investments. The firm’s portfolio covers sectors such as healthcare, AI, robotics, energy, and fintech, with notable investments in Beyond Meat, JumpCloud, and Lemonade. Beyond Meat, a leader in plant-based foods, and Lemonade, an AI-driven insurance company, both had successful IPOs and continue to thrive. OurCrowd’s investment strategy involves thorough due diligence and active support for portfolio companies, ranging from seed to growth stages. They typically invest between $1 million and $5 million, offering strategic guidance and access to a global network of co-investors and operational support​. The firm operates globally, with a strong presence in Israel and the U.S., and investments in Europe, Asia, and Latin America. This global reach allows them to tap into diverse markets and innovative ecosystems. Led by CEO Jon Medved, OurCrowd’s team includes investment professionals across multiple offices worldwide, ensuring a comprehensive approach to emerging technologies and market opportunities. Startups seeking investment should highlight their innovation, scalability, and market potential, approaching OurCrowd through their network or platform to increase funding chances

Outset Capital is a specialized early-stage venture capital firm based in San Francisco, driven by a team of AI practitioners and serial entrepreneurs. Their investment focus is on AI, dev tools, robotics, and the future of work, making them a go-to partner for cutting-edge tech startups. They are particularly known for backing companies at the earliest stages, often before anyone else, with small but strategic investments that do not lead rounds. Instead, Outset prefers to add significant value through their hands-on approach, leveraging their deep operational experience to help founders scale from 0 to 1. Notable portfolio companies include Datology AI, Reflex, and SimpleHash, showcasing their focus on AI and software innovation. Outset Capital typically co-invests with leading firms like Andreessen Horowitz, Sequoia, and Lux Capital, reflecting their strong network and collaborative approach. Led by Ali Rohde, Josh Albrecht, and Kanjun Qiu, all of whom are based in San Francisco, the team’s unique blend of technical expertise and entrepreneurial success offers startups robust support beyond just capital. They maintain an active presence in the Bay Area’s startup community, organizing events and fostering a strong network of founders, engineers, and researchers. For startups looking to partner with Outset, the team values integrity, founder alignment, and a shared vision for long-term impact, making them more than just investors—they’re builders backing builders.

Outsized Ventures is a venture capital fund based in London, specializing in deep tech and frontier technology startups that aim to tackle the world's most pressing challenges. The fund takes a unique approach by prioritizing people over technology, focusing on bold innovators who are not afraid to push boundaries. Notable investments include companies like Emitwise (carbon accounting software), Hoxton Farms (cultivated fat for meat alternatives), and Kernal Biologics (mRNA therapeutics), reflecting their commitment to groundbreaking science and technology. Outsized Ventures primarily invests in Europe, with a clear focus on early-stage ventures. Their strategy is founder-friendly, offering quick, transparent investment processes, sometimes closing deals within 48 hours. They often invest between fundraising rounds, helping founders maintain momentum without the distraction of constant fundraising. The team is led by experienced investors like Max, a former corporate lawyer and venture capitalist with extensive experience across Europe, Africa, and Asia, and Rod, a seasoned investor with a strong background in bioengineering startups. Outsized Ventures typically leads funding rounds and is known for offering "clean and unfussy" terms, making them an attractive partner for ambitious entrepreneurs aiming to make a significant impact. If you’re a visionary founder with a big dream, they’re the kind of investor who will back you all the way.

AngelList, a prominent platform for startup investments, has facilitated investments in over 2,698 startups through its innovative syndicate and fund structures. Some of its notable investments include companies like Brex, Postmates, Cruise, and PillPack, which have grown significantly in their respective industries. AngelList offers various investment opportunities, including traditional funds, syndicates, and rolling funds, allowing investors to back startups on a deal-by-deal basis. The platform has democratized early-stage investing by providing individual accredited investors access to high-quality investment opportunities, often in collaboration with top-tier venture capital firms. For instance, AngelList has supported the growth of companies like Notion, Iterable, and MoonPay, providing them with the necessary capital to scale. Their full-service fund management capabilities streamline the investment process, from fund formation to managing cap tables and tax preparation, making it easier for new and experienced investors alike to participate in venture capital.

Overwater Ventures is an early-stage venture capital firm based in San Francisco, founded and led by Kristina Simmons, a former partner at Andreessen Horowitz and Chief of Staff at Khosla Ventures. The firm focuses on investing in breakthrough technologies that positively impact human health and the planet. Overwater Ventures closed its $20 million debut fund in April 2023, with backing from institutional family offices, experienced founders, and prominent investors like Vinod Khosla. The fund primarily targets sectors such as digital health, biotech, AI, robotics, climate tech, and future food. Notable portfolio companies include Overstory, which reduces power outages and wildfires, and Conceive, a fertility technology firm. Overwater Ventures is committed to providing holistic support to its founders, addressing not just business needs like marketing and fundraising but also personal well-being, including mental health and stress management.

OVP Venture Partners (originally Olympic Venture Partners) was one of the Pacific Northwest's pioneer early-stage venture capital firms, founded in 1983 and headquartered in Kirkland, Washington, with an additional office in Portland, Oregon. Across nearly three decades of operation, OVP raised seven funds and managed more than $750 million in aggregate capital, led by Managing Directors Gerry Langeler, Chad Waite, and Bill Funcannon. The firm focused on information technology, software, digital media, communications, security, semiconductors, clean tech, and digital biology, with an emphasis on capital-efficient technology businesses in the western United States. OVP invested in approximately 102 companies across its history, generating 6 IPOs and 51 acquisitions. Early stakes in Qualcomm and Lam Research established the firm's track record. Later notable exits include NanoString Technologies (acquired by Bruker for $393 million in April 2024, OVP's most recent portfolio liquidity event), Cradlepoint, Fate Therapeutics, Aggregate Knowledge, Complete Genomics, Integrated Diagnostics, and RedSeal. The firm's seventh and final fund, OVP VII, was a $250 million 2006-vintage vehicle. In November 2012 OVP announced it would wind down and not raise an eighth fund, citing challenging fundraising conditions. OVP VII has since been liquidated. OVP Venture Partners is permanently closed to new investments. Its legacy portfolio has been fully managed to conclusion by the remaining partners, and the firm's track record stands as one of the most extensive in Pacific Northwest venture history, spanning four decades of technology investing and more than 50 successful exits across software, biotech, hardware, and communications.

Oxford Capital Partners, founded in 1999 and based in Oxford, UK, is a venture capital firm that focuses on investing in early-stage technology companies. The firm has invested approximately £500 million in over 100 businesses, emphasizing sectors such as fintech, digital health, artificial intelligence, and the future of retail. Their investment strategy leverages the UK's Enterprise Investment Scheme (EIS), providing tax advantages to investors and fostering innovation across the tech landscape. Oxford Capital seeks to back high-potential, disruptive technology with strong intellectual property or early signs of product-market fit. They typically aim to be the first institutional investor in these early-stage ventures, ranging from seed to Series A rounds. Their portfolio includes notable companies like Moneybox, Red Sift, and Attest. The firm prides itself on a hands-on approach, supporting founders with not only capital but also strategic guidance to help them achieve significant growth and scalability. The team, led by founder David Mott and including key members like Stephen Hampson and Chris Payne, brings a wealth of experience in venture capital and strategic investments. Oxford Capital's location in one of the world's leading knowledge clusters, Oxford, positions them advantageously to tap into cutting-edge innovations and support high-growth companies aiming to expand internationally.

Oxford Science Enterprises (OSE) is a venture capital firm deeply integrated with the University of Oxford, focusing on commercializing breakthrough scientific innovations. With a portfolio valued at over £2 billion, OSE invests in three core sectors: Life Sciences, Deep Tech, and Health Tech. It has partnered with over 200 leading academics from the university to build and support more than 80 high-impact companies. OSE’s strategy is to support early-stage ventures with long-term capital and hands-on expertise. Their investments span from biotechnology to quantum computing, with notable companies like Oxford Quantum Circuits, Ultromics, and Evox Therapeutics in the portfolio. OSE’s commitment to groundbreaking technologies is further emphasized by their mission to address global challenges such as health, food security, and sustainability. The firm is led by a distinguished team with deep ties to Oxford’s innovation ecosystem, including Jack Edmondson, the Chief Investment Officer, who has extensive experience managing large-scale investments at Oxford University Endowment Management. This alignment with Oxford enables OSE to identify and scale cutting-edge research into successful businesses. OSE’s model is designed to bridge the gap between academic discovery and market application, creating transformative companies that aim to improve human lives and drive future technological advancements.

Oxford Science Enterprises (OSE), previously known as Oxford Sciences Innovation, is a prominent investment company founded in 2015 with the mission to commercialize the cutting-edge research from the University of Oxford. OSE has raised over £850 million and invested around £775 million into over 45 core portfolio companies across three main sectors: Deep Tech, Life Sciences, and Health Tech. Notable investments include Vaccitech, the developer of the Oxford-AstraZeneca COVID-19 vaccine, Quantum Motion, and Beacon Therapeutics, which is advancing gene therapies for retinal diseases. OSE typically provides the first cheque to early-stage companies and supports them all the way to exit. Their strategy involves deep collaboration with Oxford University, leveraging the university's vast research capabilities to create transformative businesses. This partnership has resulted in over £1.4 billion in investment into university spinouts as of 2021, significantly increasing the scale and impact of Oxford's innovation ecosystem. The firm is committed to addressing some of the world's most significant challenges by supporting pioneering technologies and translating novel research into real-world applications. Their hands-on approach includes taking board seats and actively engaging with the founding teams to provide strategic guidance and operational support.

Oxford Technology is a venture capital firm that specializes in investing in early-stage technology-based businesses. They manage both SEIS (Seed Enterprise Investment Scheme) and EIS (Enterprise Investment Scheme) funds, providing up to £150k in seed funding for SEIS companies and up to £300k in follow-on funding for EIS companies. Their focus is on science, technology, and engineering startups, primarily within a 60-mile radius of Oxford to facilitate active involvement with the companies. Notable investments by Oxford Technology include OxWash, which is developing sustainable laundry solutions; Refeyn, pioneering mass photometry for single molecules; and HydRegen, creating bio-based manufacturing technologies. They have also invested in innovative companies like Neuroute, which aggregates data for clinical trial recruitment, and Covatic, enabling personalized content creation without the need for tracking IDs. Oxford Technology aims to maximize shareholder value by working closely with their portfolio companies to achieve successful exits and providing ongoing support. Their investment strategy not only leverages tax reliefs but also focuses on creating successful companies with significant long-term growth potential.

Oxy Capital is a Lisbon-based private equity firm with a strong focus on supporting small and medium-sized enterprises (SMEs) through tailored investment strategies. Since its founding in 2011, Oxy Capital has concentrated on restructuring, private equity, mezzanine debt, and special situations. With over 25 professionals across offices in Lisbon and Milan, the firm manages a variety of funds, including the Fundo de Reestruturação Empresarial and Oxy Capital Mezzanine Fund, which emphasize economic revitalization and sustainable growth. Oxy Capital specializes in creative financing solutions, particularly for businesses facing operational challenges or in need of restructuring. Its investment philosophy is driven by flexibility and boldness, enabling the firm to venture into under-explored markets and deliver high returns for investors. The firm’s portfolio spans industries like manufacturing, energy services, and commercial products, with a clear focus on fostering competitiveness in its portfolio companies. Led by Managing Partner Miguel Lucas, the team prides itself on its hands-on approach, working closely with businesses to enhance value while offering deep market insights. Oxy Capital’s dual presence in Portugal and Italy gives it a strong foothold in Southern Europe, making it a key player in revitalizing SMEs across the region.

Oyster Ventures, founded in 2016 and headquartered in San Francisco, is a venture capital firm that targets early-stage investments in frontier technology companies. The firm aims to drive innovation by investing in startups that bring liquidity and efficiency to traditional industries, support globalization, and have significant scaling potential. Notable companies in their portfolio include Ridepanda, Rithmm, and Advance, reflecting their diverse investment interests in specialty retail, business productivity software, and financial software. Key exits like Postmates and Clearbit highlight their success. Led by Sophie Liao and Ran Wang, Oyster Ventures is known for its hands-on approach and strategic support, helping portfolio companies navigate the complexities of growth and scale. The firm is particularly interested in technologies that can disrupt and modernize outdated systems, making industries more efficient and globally accessible. Their investment strategy focuses on identifying and nurturing startups with the potential to become market leaders through innovative solutions and robust business models. This approach has positioned Oyster Ventures as a significant player in the venture capital landscape, dedicated to fostering technological advancements and supporting visionary entrepreneurs.

P101 Ventures, founded in 2013 and based in Milan, Italy, is a venture capital firm focusing on early-stage investments in the digital and technology sectors. With over 100 million euros under management, P101 is known for its commitment to nurturing innovative startups through capital, extensive networks, and strategic advisory. P101’s portfolio includes a variety of successful companies such as Tannico, an e-commerce platform for wine; BorsadelCredito.it, a peer-to-peer lending platform; and Cortilia, an online marketplace for fresh, local food products. The firm typically invests between 1 to 5 million euros per company and reserves additional capital for follow-on investments to support the continued growth of its portfolio companies. The firm's investment strategy involves active collaboration with founders, helping them design effective growth strategies and improve their ESG performance. P101 also leverages a strong network of strategic consultants, CEOs, and industry experts to provide deep operational and business development support​.

Pacific 8 Ventures is a Taiwan-based venture capital firm, primarily focusing on healthcare and disruptive technology platforms. Founded by Jack Liang, the firm targets early-stage companies, with a preference for being the first institutional investor. Pacific 8 Ventures invests in transformative technologies, especially those reshaping therapeutics, diagnostics, and broader health services. Their investment approach is global, with a strong emphasis on the U.S. market, where disruptive healthcare innovations are burgeoning​. Pacific 8 Ventures has built a diverse portfolio of companies at the forefront of healthcare innovation. Notable investments include Mammoth Biosciences, known for its pioneering work with CRISPR technology, and BillionToOne, which revolutionizes prenatal testing. They have also invested in companies like Fauna Bio, which uses mammalian genetic data for novel therapeutics, and Dorian Therapeutics, focused on anti-aging technologies. The firm is also involved in significant collaborations, such as Mammoth Biosciences' $1 billion partnership with Bayer. Pacific 8 Ventures is dedicated to helping companies navigate the challenges of scaling in the competitive healthcare landscape, leveraging deep expertise and strategic support to drive success.

Page One Ventures is an early-stage Silicon Valley venture capital firm founded in 2020 by General Partner Mo El-Bibany and headquartered in San Francisco. The firm invests in software transforming existing markets and in deep technology creating entirely new ones, with stated focus areas in life sciences, deep tech, and B2B SaaS, with particular emphasis on data infrastructure and AI. Its thesis, captured in the firm's own phrasing, is that the future will be 'written in code and in codons,' reflecting a deliberate barbell between software and biology or hardware frontiers. The team of seven spans the United States and United Kingdom, with Venture Partners Ameena El-Bibany and Marc-Alexandre Saba complementing the founding GP. Through prior funds, the partners have backed more than 50 companies that have gone on to raise more than $1.5 billion in follow-on financing at an aggregate enterprise value exceeding $20 billion. As of October 2025, the Page One portfolio numbered approximately 68 companies across seed and Series A, including five unicorns and five acquired companies. Headline names include Dapper Labs, DataRobot, Ayar Labs (which reached unicorn status in 2024), and Portal Biotechnologies. The most recent reported new investment is GRO Biosciences in July 2024, and the most recent exit was Teampay, acquired by PayStand in April 2024. Page One takes a conviction-driven, founder-centric approach, deploying across both pre-seed and seed stages. The firm's interdisciplinary perspective across software and life sciences allows it to evaluate companies at the intersection of biology and computation that generalist funds may be poorly positioned to underwrite.

Paladin Capital Group is a global venture capital firm based in Washington, D.C., with additional offices in New York, Silicon Valley, London, and Luxembourg. Since its inception in 2001, Paladin has managed over $1 billion in committed capital, investing in more than 65 companies across North America, Europe, Australia, and South America. The firm focuses on innovative technology, particularly in cybersecurity, which has become a primary area of expertise. Notable investments include Corellium, which specializes in mobile and IoT virtualization; Digital Shadows, a provider of cyber situational awareness; and Expel, a company offering transparent managed security. Other significant portfolio companies include RangeForce, which offers a cyber simulation and skills analytics platform, and Hack The Box, an online cybersecurity training platform. Paladin Capital Group employs a dual-use investment approach, leveraging its knowledge of both commercial and government markets to provide unique insights and opportunities for its portfolio companies. This strategy helps startups develop strategic partnerships, access new markets, and navigate financing options. The firm is committed to adding value beyond capital by supporting portfolio companies with strategic guidance and leveraging its extensive network to maximize returns. Paladin has been actively involved in numerous successful exits, including the sale of Hubble Technologies to KKR-backed NetSPI.

Pale Blue Dot is a venture capital firm based in Malmö, Sweden, focused on early-stage investments in climate tech startups. Founded in 2020 by Joel Larsson, Heidi Lindvall, and Hampus Jakobsson, the firm aims to back founders addressing one of the most pressing global challenges: climate change. Pale Blue Dot invests in seed and pre-seed stage companies, typically with ticket sizes ranging from €500,000 to €2 million. They target businesses that offer scalable, innovative solutions to mitigate or reverse the effects of climate change. The firm’s portfolio spans diverse sectors, including foodtech, agtech, energy, logistics, and biotech, with notable investments in companies such as Monta, Hived, and Overstory. Their strategy involves leading or co-leading rounds, with a focus on companies based in Europe and the US. Pale Blue Dot has two funds: Fund I (€87 million) and Fund II (€93 million), demonstrating their commitment to investing in businesses that not only turn a profit but also have a significant, positive environmental impact. The fund places a strong emphasis on diversity and inclusion, aiming to back visionary leaders building sustainable and equitable companies. Their mission is to invest in technologies that will shape a future where every business operates as a net positive for the planet, aligning profit with impact. Pale Blue Dot views the climate crisis not just as a challenge, but as an opportunity to build the next generation of billion-dollar companies driving real-world change.

Pallasite Ventures is a venture capital firm that focuses on providing early-stage financing to high-growth companies across a variety of industries, including tech and consumer products. Founded in 2012 and based in Vancouver, Canada, Pallasite Ventures aims to fund companies whose leaders have the vision and skill to transform their markets. The firm is particularly active in Seed and Series A deals, offering investments ranging from $100,000 to $1.5 million USD and maintaining significant reserves to support their portfolio companies as they grow. The firm has invested in over 60 companies, including notable names like Dooly, Prescryptive, and CalypsoAI. Pallasite Ventures places a strong emphasis on adding value and providing support to its portfolio companies, ensuring they have the resources and freedom needed for long-term growth. The firm's investment focus spans multiple regions, including Vancouver, San Francisco, Boston, Denver, Chicago, and Toronto. Pallasite Ventures is led by Managing Partner Christopher Bissonnette, Ph.D., and operates with an agile and supportive approach, aiming to streamline decisions and provide strategic advice to its investments​.

Palo Santo is a venture capital firm specializing in psychedelic healthcare and therapies, with a mission to revolutionize mental health treatment. Founded in 2020, Palo Santo operates with a clear focus on advancing the development of psychedelic-based treatments for conditions like depression, PTSD, and addiction. With an initial fund of $35 million, the firm supports a wide range of companies working on groundbreaking solutions in biopharma, digital therapeutics, and healthcare services. Their portfolio includes over 20 companies such as atai Life Sciences, Field Trip Health, Bexson Biomedical, and Reset Pharma. The firm’s leadership is guided by top-tier experts in the psychedelic space, including Co-Founder Tim Schlidt, who is passionate about expanding access to mental health treatments. They are supported by a renowned advisory board made up of thought leaders like Dr. Charles Nichols, a professor and pioneering researcher in psychedelics, and Dr. Julie Holland, a psychiatrist and author focused on drug policy reform and clinical research into psychedelic therapies. This interdisciplinary approach enables Palo Santo to navigate the complex regulatory and scientific challenges in this emerging industry. Palo Santo's strategy emphasizes not just the scientific advancement of psychedelics, but also their affordability and accessibility for patients. They aim to scale clinically effective treatments by investing in companies that are making significant strides in the mental health sector. Their goal is to bring psychedelic therapies into the mainstream, addressing the growing global mental health crisis with innovative, science-backed solutions.

Panacea Venture is a global healthcare-focused venture capital fund with a strong track record in early-stage life sciences investments. Spun out of Kleiner Perkins, Panacea specializes in building innovative companies that target unmet medical needs, particularly in biotech, therapeutics, and medical devices. Their investment scope spans cell and gene therapies, diagnostics, and emerging technologies like AI-driven healthcare solutions. With a global reach, Panacea has offices in Shanghai, Boston, and Silicon Valley, leveraging its cross-border expertise to tap into transformative healthcare innovations across North America and Asia. The firm is highly active, leading early-stage rounds and often taking board seats, while its venture operator model allows them to incubate and actively manage portfolio companies. Notable portfolio names include groundbreaking companies in immunotherapy and gene editing, such as TriArm Therapeutics and Kindstar Global. Panacea’s investment approach focuses on deep due diligence and long-term partnerships. They seek companies with strong scientific foundations and scalable technologies, preferring founders with deep domain expertise. The fund’s managing partner, James Huang, along with a diverse team of venture partners, brings over 100 years of combined experience in both venture capital and life sciences industries. They continue to focus on early-stage growth, with an emphasis on hands-on involvement to drive value from inception to public market success.

Panache Ventures is a leading Canadian venture capital firm specializing in early-stage investments, particularly at the pre-seed and seed stages. Founded in 2018, the firm has a strong national presence with offices in Vancouver, Calgary, Toronto, and Montreal. Panache Ventures focuses on supporting ambitious entrepreneurs across various sectors, including enterprise software, AI/ML, fintech, blockchain/web3, health tech, and climate tech. Panache Ventures' first fund raised over $58 million and invested in 100 companies, achieving notable exits such as fintech company Flinks and proptech company Lane. Their second fund, Panache Ventures II, closed at $100 million, with significant investments from Alberta Enterprise Corporation, Ontario Capital Growth Corporation, Investissement Québec, BMO Financial Group, and TELUS Ventures. This fund aims to double down on pre-seed and seed investments in Canadian technology startups, supporting around 20 new investments per year​. The firm is known for its commitment to diversity and inclusion, with 52% of its portfolio companies being led by persons of color and a rate of investment in women-led startups that is 1.8 times the national average for Canadian venture capital​​. Panache Ventures emphasizes a founder-friendly approach, providing extensive mentorship and support throughout the growth of their portfolio companies. Key team members include Chris Neumann, Scott Loong, Prashant Matta, and Patrick Lor, who collectively bring a wealth of experience and expertise to the firm.

Panakès Partners, based in Milan, is a leading venture capital firm specializing in life sciences. Founded by Diana Saraceni, who has over 20 years of experience in the VC industry, the firm focuses on early-stage startups and SMEs developing innovative technologies in biotech, diagnostics, and medical devices. Their portfolio includes notable investments like EndoStart and Diadem, reflecting their commitment to groundbreaking solutions in healthcare. Panakès primarily targets Europe and Israel, aiming to address significant unmet medical needs with a robust ESG framework. Their latest €175 million fund, the Purple Fund, emphasizes Series A investments, supporting around 15-18 companies with average checks ranging from €5 to €10 million. Known for leading rounds, Panakès actively engages with startups through a rigorous selection process, valuing sustainability and impactful health solutions. The team, led by Saraceni, brings extensive expertise and a strong network in the life sciences sector, bolstered by their participation in various national and international advisory boards. For entrepreneurs, Panakès is approachable via direct submissions to their email, fostering a transparent and accessible investment process.

Pangaea Ventures is a world-leading hard-technology venture capital firm founded in 2000 by Founding General Partner Chris Erickson (formerly a partner at Osler, Hoskin and Harcourt specializing in environmental and corporate law), Purnesh Seegopaul, and David Weekes. Headquartered in Vancouver, British Columbia with an additional office in Phoenix, Arizona, the firm backs early-stage companies leveraging advancements in advanced materials, chemistry, and biology to address large global challenges and enable a sustainable future. Across five funds, the firm has targeted multi-trillion-dollar market opportunities in energy, electronics, health, and sustainability. Fund IV was a $100 million vehicle, and Fund V, the Pangaea Ventures Impact Fund, held its final close in April 2024 at CAD 115 million, planning approximately 10 to 12 Series A investments with typical checks of $3 million to $5 million. Pangaea leads rounds and operates with a team of 16, including six partners such as Andrew Haughian, who joined in 2006 and leads materials-science coverage. The firm has invested in 42 companies and has recorded 12 portfolio exits to date. Portfolio highlights include Aspect Biosystems (bioprinted tissue), Calysta (gas-fermentation protein), CarbonCure (carbon-sequestering concrete, with $169 million-plus raised), ESS (iron flow batteries), Redlen Technologies (medical imaging), Vestaron (bio-pesticides), and Nautilus Data Technologies. In 2025 the firm completed three new investments, with the most recent being pH7 Technologies' Series B in December 2025. Pangaea Ventures brings deep technical diligence capability, scientific networks, and long-duration patient capital to founders commercializing laboratory breakthroughs in materials and chemistry. Its specialist positioning within hard tech makes it one of the few funds globally with the expertise and conviction to lead seed and Series A rounds in the advanced-materials category.

Pappas Capital is a prominent venture capital firm based in Durham, North Carolina, specializing in investing in next-generation life science, agriculture, and technology companies. Established in 1994 by Art Pappas, the firm has a robust track record of investing in over 90 companies across the United States, Canada, and Asia. Their investments focus on innovative solutions that address significant unmet medical needs and span a wide range of diseases, including cancer and hemophilia​. Pappas Capital operates through three primary divisions: Pappas Ventures, Specialized Fund Management, and Translational Medicine. Pappas Ventures is their flagship arm, dedicated to life science investments, particularly in undercapitalized markets. Specialized Fund Management creates and manages custom investment vehicles, while Translational Medicine partners with academic institutions to accelerate the development of scientific discoveries. The firm boasts a seasoned team of investment professionals, including Art Pappas, Elizabeth Kelly, and Barry Myers, who bring extensive experience in pharmaceuticals, biotechnology, and venture capital. This expertise enables Pappas Capital to provide valuable insights and strategic guidance to their portfolio companies, helping them navigate the complexities of drug development and commercialization. Pappas Capital has successfully guided numerous companies to significant exits, including IPOs and acquisitions. Recent investments include companies like VFlow Tech and Enlaza Therapeutics, further emphasizing their commitment to advancing groundbreaking life science technologies​.

Pareto Holdings, founded by Edward Lando and Jon Oringer in 2020, is a Miami-based venture capital firm specializing in early-stage investments. The fund has a dynamic portfolio that includes notable companies such as Burnbot, nsave, and Elevated Signals, reflecting its focus on Environmental Services (B2B), Financial Software, and Business/Productivity Software industries. Pareto Holdings primarily targets startups with high potential for globalization, emphasizing early growth companies with significant momentum. Geographically, the firm maintains a strong presence in the U.S., with a particular focus on the Miami entrepreneurial ecosystem. The investment strategy at Pareto Holdings involves being one of the first backers of exceptional entrepreneurs. They typically lead funding rounds and are known for their active involvement in their investments. The average check size varies, but they maintain a hands-on approach, often participating in the operational aspects of the startups they invest in. Approaching Pareto Holdings requires demonstrating high growth potential and a clear path to global expansion. They value innovation and market disruption, looking for teams that can leverage their extensive network and resources effectively. The leadership team at Pareto Holdings includes Edward Lando, Jon Oringer, Rohit Bhadange, Annie Wasserman, and Benjamin-Jean Cambier, all based in Miami. This diverse team brings a wealth of experience in venture capital and business development, ensuring robust support for their portfolio companies.

Parkwalk Advisors, founded in 2009, is a leading UK-based growth fund manager specializing in investments in university spin-outs. With over £500 million raised and investments in more than 180 companies, Parkwalk focuses on high-growth, knowledge-intensive sectors such as AI, big data, life sciences, cleantech, and quantum computing. Parkwalk's notable portfolio companies include Bramble Energy, a clean energy technology provider; AccelerComm, a semiconductor chip design company; and PetMedix, a veterinary biopharmaceutical company. These investments highlight Parkwalk's commitment to fostering innovation in deep tech and science sectors. The firm manages various funds, including the Parkwalk Opportunities EIS Fund and the Knowledge Intensive EIS Funds, which offer tax benefits under the Enterprise Investment Scheme (EIS). These funds aim to support the commercialization of technologies emerging from the UK's top universities, such as Oxford, Cambridge, Imperial College, and UCL. Parkwalk's approach to investing includes providing strategic support and leveraging their extensive network to help portfolio companies achieve their full potential. They have been the largest single EIS fundraise for several years, demonstrating their pivotal role in the UK’s venture capital landscape.

Partech is a global venture capital firm with a strong focus on technology startups, operating across several investment stages—Seed, Venture, Growth, and Impact. Its portfolio includes notable companies such as Akeneo, a leader in product information management, and ManoMano, Europe's top online marketplace for DIY and gardening products. With offices in San Francisco, Paris, Berlin, and Dakar, Partech invests worldwide, with a special focus on Europe and Africa. The firm’s seed-stage investments typically range from €300k to €3M, with Partech taking a hands-on approach to support startups from the earliest stages. In the growth phase, they invest larger amounts—up to €100M—to scale high-growth companies like Rohlik Group, a rapidly expanding online grocery delivery service. Partech also leads the way in African tech investments, backing companies such as Wave Sénégal, a leading mobile money provider. Their impact fund focuses on scaling companies addressing environmental and social challenges, with investments ranging from €15M to €40M.

Pascual Innoventures is the corporate venturing arm of the Pascual Group, dedicated to investing in innovative startups within the food and agriculture sectors. With a focus on disrupting traditional food systems, they target areas like alternative proteins, food tech, and agritech. The firm is particularly interested in technologies that promote sustainability and improve human health, such as precision fermentation and functional ingredients. Their portfolio includes startups like Zero Cow Factory, which develops dairy proteins using fermentation, and DeNovo Foodlabs, which focuses on nutrition solutions. Pascual Innoventures also runs "Mylkcubator," the world’s first incubator focused on dairy industry innovation, supporting startups in cellular agriculture and fermentation technologies. The fund offers more than just capital by providing startups with extensive operational support, including marketing, HR, and legal assistance, as well as access to R&D facilities. Led by Gabriel Torres Pascual, a third-generation member of the Pascual family, the firm aims to create long-term impact by nurturing startups from concept to market.

Pathbreaker Ventures, established in 2016 and based in San Francisco, focuses on early-stage investments in startups tackling significant global challenges with innovative hardware and software solutions. Led by Ryan Gembala, the firm supports specialized engineering and product leaders, often investing when a company is still in its foundational stage. Pathbreaker invests in sectors like AI, robotics, and deep tech, targeting problems valued at over $100 billion​. Ryan Gembala, the Founder and Managing Partner, has a rich background in venture capital and corporate development, having previously worked at Facebook and Azure Capital. His experience spans the full startup lifecycle, from founding and operating companies to investing and acquiring venture-backed firms​. Pathbreaker Ventures' portfolio includes companies like Spiketrap, an AI for real-time language understanding, and Mux, which builds video streaming and analytics APIs. The firm co-invests with top-tier venture firms and is known for its hands-on approach, providing capital, strategic advice, and access to a vast network of industry experts.

Paua Ventures, now rebranded as SquareOne, is a Berlin-based venture capital firm that focuses on pre-seed and seed-stage investments. Established in 2010, SquareOne primarily backs B2B tech startups, emphasizing sectors like SaaS, deep tech, and enterprise software. The firm is often the first institutional investor on the cap table, acting as a strategic partner for founders throughout the company's early development stages. SquareOne is known for offering more than just capital. The firm prides itself on being a hands-on partner, providing operational support, mentorship, and valuable connections within its extensive network of executives and industry experts. This proactive involvement helps founders navigate the complexities of scaling their businesses, and many of SquareOne’s portfolio companies go on to secure follow-on funding from top-tier European and U.S. investors. The firm has a strong track record, with notable investments including Pipedrive, Stripe, and Lesara. SquareOne typically invests in European startups but has a global outlook, supporting innovative companies that have the potential to lead in their industries. Christian Buchenau and Moritz Poewe are among the key partners at SquareOne, guiding the firm’s investment strategy and maintaining its reputation as a leading early-stage investor in Europe. By providing a combination of capital, strategic insight, and market access, SquareOne is positioned as a vital player in the European venture capital landscape, helping startups reach their full potential.

PBM Capital, founded by entrepreneur Paul Manning in 2010, is a dynamic healthcare-focused investment firm with a strong emphasis on pharmaceuticals, biotechnology, and life sciences. Headquartered in Charlottesville, Virginia, with an additional office in New York, PBM partners with scientists and innovators to create groundbreaking therapies that significantly improve patient outcomes. Their team provides capital along with critical operational and strategic expertise, helping companies navigate complex healthcare markets and scale rapidly. PBM’s portfolio boasts several notable successes, including AveXis, which was acquired by Novartis for $8.7 billion, and Dova Pharmaceuticals, which completed an IPO before being acquired by Swedish Orphan Biovitrum. The firm seeks out companies with revolutionary science and strong leadership, focusing on areas such as gene therapy, biologics, and drug development. PBM takes an active role in guiding its investments, offering not only funding but also leveraging its extensive network to accelerate commercialization. Their investment strategy centers around long-term value creation, seeking out companies with life-changing technologies and the potential to transform healthcare. By combining operational experience with capital investment, PBM aims to help founders bring revolutionary therapies to market and create lasting impact​.

PeakBridge VC is a venture capital firm focused on Agri-FoodTech, investing in companies that address major challenges in the global food system. Founded in 2016 and headquartered in Malta, PeakBridge aims to create long-term impact by investing in startups that drive sustainable solutions, improving both environmental and health outcomes across the food chain. The firm’s investment strategy is centered on five key areas: ingredient innovations, alternative protein technologies, food system digitalization, nutrition & health, and alternative farming systems. By investing in these sectors, PeakBridge helps startups scale solutions that tackle issues such as food waste, nutrition deficiencies, and the carbon footprint of food production. Its portfolio includes innovative companies like Standing Ovation (dairy substitutes through microbial fermentation), Vow (cultured meat), and Rival Foods (plant-based protein). PeakBridge operates through its FoodSparks® Seed Fund for early-stage European and Israeli startups, and Growth II Fund for Series A-B investments in Europe, the U.S., and Israel. The firm’s total assets under management exceed $250 million, with significant backing from Edmond de Rothschild Private Equity. As an Article 9 fund under the Sustainable Finance Disclosure Regulation (SFDR), PeakBridge integrates strict ESG principles into its investments, ensuring all portfolio companies contribute to a healthier and more sustainable food system.

Pear VC (formerly Pejman Mar Ventures) is one of Silicon Valley's most respected pre-seed and seed specialist venture firms, founded in August 2013 by Pejman Nozad and Mar Hershenson and rebranded from Pejman Mar to Pear VC in August 2016 with the launch of its $75 million Fund II. Headquartered in Menlo Park, California, the firm leads rounds and has scaled its fund platform from a $50 million first fund to $160 million (Fund III) and an oversubscribed $432 million Fund IV closed in 2023, bringing cumulative capital raised to roughly $700 million. The 25-person team includes Founding Managing Partners Pejman Nozad and Mar Hershenson and Partner Kathleen Estreich. Pear operates an explicit three-stage framework covering pre-seed through Series A and has built distinctive sourcing programs including PearX, Pear Pre-Seed Ready, and an Emerging Managers in Residence program launched in September 2024. Across 263 investments Pear has seeded three public companies: DoorDash, Guardant Health, and Senti Biosciences. Additional billion-dollar breakouts from the portfolio include Gusto, Branch, Aurora Solar, and Vanta. In 2025 the firm made 34 new investments, with seven more in the first quarter of 2026. The firm has recorded 27 portfolio exits to date, including BioAge Labs and Voyage AI. The most recent liquidity event was the exit of Breakout Audio in May 2025. Pear VC combines high-frequency seed deployment with deep programmatic engagement, running accelerator-style programs that give the firm proprietary access to emerging founders before they reach the market. The result is a sourcing advantage built over a decade of community investment in Stanford, MIT, and the broader Silicon Valley founder ecosystem.

Pebblebed is an early-stage venture capital firm founded in 2022, based in San Francisco, California. The firm focuses on investing in technology companies that demonstrate profound technical insight and have the potential to build long-term competitive advantages. Pebblebed targets investments in companies that create significant value through innovation, aiming to support startups that are capable of developing strong market positions and enduring customer relationships. Pebblebed is particularly interested in businesses that can establish deep end-user stickiness, build strong brand loyalty, or create high switching costs for customers, thereby ensuring sustainable growth and market leadership. The firm’s investment strategy is characterized by its emphasis on deep technical knowledge, leveraging the expertise of its partners who have extensive backgrounds in engineering and technology. The firm has made several investments across various sectors, including AI, computing infrastructure, and other tech-driven industries. Pebblebed’s approach is to provide more than just capital; it aims to be a strategic partner to its portfolio companies, offering guidance and resources to help them scale and succeed in competitive markets.

Pegasus Tech Ventures, based in Silicon Valley, is a global venture capital firm managing over $2 billion in assets. Founded in 2011, Pegasus offers a unique Venture Capital-as-a-Service (VCaaS) model, partnering with large corporations to invest in emerging tech startups. This involves vetting investment opportunities, managing investments, and connecting startups to a network of over 30 international corporate partners to accelerate growth. Notable investments include high-profile companies such as SpaceX, Twitter, Airbnb, SoFi, DoorDash, and 23andMe. Pegasus' diverse portfolio spans sectors like consumer electronics, automotive, healthcare, AI, and fintech, reflecting its broad investment strategy. Recently, Pegasus launched a $100 million fund with Denka Company Limited, focusing on ICT, energy, healthcare, and sustainable living. This fund aims to invest in startups across the US, Europe, Israel, and Asia, enhancing Denka's growth and innovation efforts. Additionally, Pegasus founded and sponsors the Startup World Cup, one of the largest startup competitions globally, with a $1 million investment prize. This competition supports regional innovation ecosystems worldwide and connects them to Silicon Valley. Led by founder and CEO Anis Uzzaman, Pegasus leverages its extensive global network and deep tech expertise to drive corporate innovation and help emerging tech companies achieve industry leadership.

Pentech Ventures is a premier venture capital firm headquartered in Edinburgh with a strong presence in London. They specialize in seed and early-stage investments, primarily targeting innovative software companies. Known for their notable exits like FanDuel, Nutmeg, and Maxymiser, Pentech has a reputation for nurturing companies that redefine their industries. Pentech focuses on UK-based startups across various software domains, including fintech, AI, and SaaS. They typically invest around £1M, often leading rounds and collaborating in syndicates. Their strategy involves not just capital infusion but also strategic guidance, leveraging their extensive network to introduce additional funding partners for subsequent growth stages. The team is led by founding partner Eddie Anderson, alongside experts like Alexander McKinnon and Craig Anderson, all based in Edinburgh. Their deep expertise spans machine learning, enterprise infrastructure, and SaaS business models, providing invaluable support to portfolio companies. For startups seeking investment, Pentech values ambitious leadership and category-defining potential. They prefer to be approached with clear, concise pitches that demonstrate strong market potential and scalability. Active and engaged, Pentech remains a dynamic force in the venture capital landscape, continuously seeking to empower the next generation of software pioneers.

Perceptive Xontogeny Venture Fund (PXV) is the early-stage life-sciences venture capital platform of New York-based Perceptive Advisors, operated in strategic partnership with Boston-based accelerator and operating company Xontogeny. Perceptive Advisors launched its venture strategy with Perceptive Xontogeny Venture Fund I in 2018, an oversubscribed $210 million vehicle backed by endowments, foundations, family offices, and institutional investors. Fund II closed in May 2021 at $515 million, bringing the combined platform to more than $700 million dedicated to financing early-stage private life-sciences companies. The Investment Committee is anchored by Joe Edelman (CEO of Perceptive Advisors), Adam Stone (CIO of Perceptive Advisors), and Chris Garabedian (Portfolio Manager and Chairman and CEO of Xontogeny), alongside operating partners Fred Callori and Ben Askew, PhD. The platform leads rounds and invests typical checks of $10 million to $20 million, targeting 8 to 10 concentrated positions per fund across biotechnology, medtech, digital health, and healthcare tools and services. Across its 27 investments, PXV has backed Landos Biopharma (the first Xontogeny company, acquired by AbbVie in May 2024 as the platform's headline exit), Lexeo Therapeutics (which entered a partnership with venBio Partners in June 2025 providing up to $40 million for novel cardiac RNA therapeutics), and other early-stage therapeutics companies. Xontogeny's operating role distinguishes PXV from traditional life-sciences funds: the platform provides deep operational support from the pre-company stage through clinical and commercial scale-up, allowing the investment team to co-build companies alongside founders rather than simply writing checks and attending board meetings.

Peregrine Ventures is Israel's first dedicated healthcare-focused venture capital fund, founded in 2001 in Or Yehuda by serial entrepreneur brothers Eyal Lifschitz (Co-Founder and General Managing Partner) and Boaz Lifschitz (Co-Founder and General Partner), who previously co-founded biomedical device companies Visioncare Ophthalmic Technologies and BioControl in the 1990s. The firm today manages approximately $600 million in assets across a multi-fund platform that pairs early-stage venture investing with Peregrine Growth, a $300 million late-stage life-sciences fund launched in November 2020, plus earlier funds including a $115 million med-tech vehicle. Partners Tamir Tal, Lior Shahory, David Eldar, and Shiran Tehila Mashiah complement the founding team. A distinctive feature of the platform is its embedded synergy with the Incentive Incubator, giving portfolio companies deep operating support from the pre-company stage through clinical and commercial scale-up. Peregrine leads rounds and has made approximately 172 investments into around 75 active and realized portfolio companies, with one unicorn, one IPO, and 16 acquisitions to date. Notable outcomes include Insightec, Quicklizard, and Eledon. Startup Nation Central named Peregrine Israel's most active healthtech investor for 2024, based on 15 strategic health-tech deals. The investment scope covers life sciences broadly: healthcare, digital health, medical devices, therapeutic devices, pharma, biotechnology, and medical software. Recent investments include Lutris Pharma ($30 million, January 2025) and Aluma Healthcare in September 2025. Peregrine's 25-year track record in Israeli healthcare and its deeply integrated incubator model create a continuum from scientific concept to clinical validation that few other investors can offer. By maintaining active involvement at every stage from incubation through growth equity, the firm builds durable portfolio relationships that extend well beyond a standard investment horizon.